Results 51 to 60 of about 2,141 (187)

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény   +10 more
wiley   +1 more source

Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial

Acta Dermato-Venereologica
There is a paucity of data regarding the use of Janus kinase inhibitors in elderly patients with moderate-to-severe atopic dermatitis necessitating systemic therapy.
Quanhong Zhang, Yue Zhu, Luoyao Yang, Yueping Zeng, Hongmei Zhang, Lang Yu, Gang Hu, Lei Hu, Liuqing Chen, Jinbo Chen   +9 more
doaj   +1 more source

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib

Pediatric Dermatology, EarlyView.
ABSTRACT Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near‐complete resolution of the psoriatic lesions with ...
Grigorios Theodosiou, Åke Svensson
wiley   +1 more source

Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

, 2023
WHAT IS THIS SUMMARY ABOUT?: Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable.
Thyssen, JP, Blauvelt, A, Rice, ZP, Katoh, N, Reich, K, Hong, HC-H, Soong, W, Valenzuela, F, Eyerich, K,, DiBonaventura, M   +9 more
core   +2 more sources

Severe exacerbation of facial dermatitis with swelling following introduction of abrocitinib in a patient with atopic dermatitis

Allergy, Asthma & Clinical Immunology
Background Abrocitinib, an oral small-molecule Janus kinase 1 (JAK1) inhibitor, has been widely accepted for the treatment of moderate-to-severe atopic dermatitis (AD).
Shirui Chen, Chongtu Yang, Yonghong Lu
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Evidence Summary of Pruritus Management in Patients With Atopic Dermatitis: Implications for Nursing Practice

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background To synthesize the most current and relevant evidence regarding pruritus management in patients with atopic dermatitis (AD), and to identify implications for nursing assessment, education, monitoring, and follow‐up. Method An extensive literature search was conducted across multiple databases, including the Cochrane Library, Embase ...
Yuzhen Shen, Qian Shen, Manni Chen, Rufang Liu   +3 more
wiley   +1 more source

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)

Journal of Dermatological Treatment
Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with ...
Luigi Gargiulo, Luciano Ibba, Angela Alfano, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Francesca Barei, Anna G. Burroni, Stefano Caccavale, Piergiacomo Calzavara-Pinton, Maria Esposito, Maria C. Fargnoli, Silvia M. Ferrucci, Caterina Foti, Giampiero Girolomoni, Massimo Gola, Mario B. Guanti, Carlotta Gurioli, Manfredi Magliulo, Martina Maurelli, Pietro Morrone, Maria L. Musumeci, Maddalena Napolitano, Michela Ortoncelli, Cataldo Patruno, Bianca M. Piraccini, Elena Pezzolo, Simone Ribero, Mariateresa Rossi, Paola Savoia, Claudio Sciarrone, Benedetta Tirone, Marco Vaccino, Federica Veronese, Antonio Costanzo, Alessandra Narcisi   +35 more
doaj   +1 more source

Signaling Pathway–Biomarker Coupling for Precision Therapy in Rheumatoid Arthritis: Mechanistic Insights, Translational Bottlenecks, and Emerging Strategies

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease. Despite advances in targeted therapies, significant interindividual variability in treatment response and a lack of precise predictive tools limit the achievement of treat‐to‐target goals.
Shijie Meng, Feng Xing, Yuyang Luo, Jianxin Li, Yingchen Ni, Fengyuan Zhang, Hua Xu, Youhua Wang, Weidong Zhang   +8 more
wiley   +1 more source